Inmode Ltd
F:154
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.34
18.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Inmode Ltd
InMode Ltd., founded in 2008, has emerged as a dynamic player in the field of minimally invasive aesthetic medical treatments. Born during a period where the health and beauty sectors were experiencing rapid technological innovation, the company quickly carved a niche for itself by addressing a clear market need: the rising demand for non-surgical procedures. At its heart, InMode merges the precision of medical technology with the principles of aesthetic enhancement. Its primary offerings revolve around radio-frequency-based devices that healthcare providers use to achieve results that traditionally required more invasive techniques. This includes skin tightening, fat reduction, and body contouring solutions, all tailored to meet the growing consumer appetite for treatments that carry less downtime and risk compared to conventional surgery.
The company monetizes its expertise by manufacturing and selling these state-of-the-art devices to a diverse group of users, ranging from dermatologists and plastic surgeons to aesthetic practices. InMode's revenue streams are bolstered by not only the direct sale of these devices but also by ongoing client relationships through service agreements and consumable products that are essential for their machine operation. It is a model that ensures continuous engagement with their clients, providing both stability and growth in revenue. By focusing on innovation and efficacy, InMode has successfully captured a significant share of the aesthetic medical market, embodying a business strategy that combines cutting-edge technology with practical solutions to consumer needs.
InMode Ltd., founded in 2008, has emerged as a dynamic player in the field of minimally invasive aesthetic medical treatments. Born during a period where the health and beauty sectors were experiencing rapid technological innovation, the company quickly carved a niche for itself by addressing a clear market need: the rising demand for non-surgical procedures. At its heart, InMode merges the precision of medical technology with the principles of aesthetic enhancement. Its primary offerings revolve around radio-frequency-based devices that healthcare providers use to achieve results that traditionally required more invasive techniques. This includes skin tightening, fat reduction, and body contouring solutions, all tailored to meet the growing consumer appetite for treatments that carry less downtime and risk compared to conventional surgery.
The company monetizes its expertise by manufacturing and selling these state-of-the-art devices to a diverse group of users, ranging from dermatologists and plastic surgeons to aesthetic practices. InMode's revenue streams are bolstered by not only the direct sale of these devices but also by ongoing client relationships through service agreements and consumable products that are essential for their machine operation. It is a model that ensures continuous engagement with their clients, providing both stability and growth in revenue. By focusing on innovation and efficacy, InMode has successfully captured a significant share of the aesthetic medical market, embodying a business strategy that combines cutting-edge technology with practical solutions to consumer needs.
Revenue Drop: Q3 2025 revenue was $93.2 million, down from $130.2 million last year, with the prior period boosted by $31.9 million in preorder sales.
Margins Under Pressure: Gross margin fell to 78% from 82% last year, impacted by tariffs as expected.
Geographic Expansion: New subsidiaries opened in Argentina and Thailand, with international sales rising 10% year-over-year to $40 million.
Consumables Strength: Consumables and service revenues grew 26% year-over-year to $19.9 million, mainly outside the U.S.
Operating Expenses Down: Operating expenses decreased 11% year-over-year to $51.4 million.
2025 Guidance Maintained: Full-year revenue guidance of $365–375 million was reiterated, with no change to margin or EPS guidance.
Leadership Change: Michael Dennison appointed as President of North America to unify management across the region.
Product Pipeline: New lasers and men’s wellness platforms are rolling out, with more launches expected in early 2026.